The inhibition of the SIRT1/PGC-1α/NRF2 pathway via the suppression of PPAR-γ transcriptional activity was reported to increase the susceptibility of wild-type P53-harboring cancer cells to oxidative stress and therapeutic agents (165). The gene discussed is PPARGC1A; the disease is cancer.